Mayinglong Pharmaceutical Group Co., Ltd. (SHA:600993)

China · Delayed Price · Currency is CNY

22.51

-0.14 (-0.62%)

Sep 10, 2026, 2:55 PM CST

Market Cap	9.76B -16.0%
Revenue (ttm)	3.93B +4.8%
Net Income	600.88M +7.4%
EPS	1.39 +6.2%
Shares Out	431.05M
PE Ratio	16.29
Forward PE	14.66
Dividend	0.70 (3.04%)
Ex-Dividend Date	Aug 5, 2026

Volume	3,217,540
Open	22.60
Previous Close	22.65
Day's Range	22.38 - 22.65
52-Week Range	21.22 - 30.18
Beta	0.23
Analysts	Strong Buy
Price Target	37.74 (+67.66%)
Earnings Date	Aug 26, 2026

About SHA:600993

Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells pharmaceutical packaging materials, cosmetics, and Chinese medicines; produces and sells health food; and offers... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1582

Employees 2,544

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600993

Full Company Profile

Financial Performance

In 2025, SHA:600993's revenue was 3.87 billion, an increase of 3.72% compared to the previous year's 3.73 billion. Earnings were 581.49 million, an increase of 10.11%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 600993 stock is "Strong Buy." The 12-month stock price target is ¥37.74, which is an increase of 67.66% from the latest price.

Price Target

¥37.74

(67.66% upside)

Analyst Consensus: Strong Buy

Stock Forecasts